A chronological record of peer-reviewed GHK-Cu research — trial types, sample sizes, and measured outcomes. This page summarizes what has been studied, not what users should expect to experience.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
Peptide research timelines are often misrepresented online. Claims about "how quickly GHK-Cuworks" usually blend anecdotal reports with selective trial data. This page restricts itself to what peer-reviewed studies measured, over what duration, with what sample size, and what the authors concluded. Readers should not infer personal results from these numbers.
Primary mechanism studied: Copper-Dependent Gene Modulation. Primary indications investigated: Skin rejuvenation, Wound healing, Hair growth, Anti-aging.
Preclinical study showing GHK-Cu reversed age-related skin atrophy and restored youthful skin architecture.
Phase 2 trial showing inhaled GHK-Cu improved lung function and reduced inflammatory markers in COPD patients.
Study demonstrating GHK-Cu enhanced cellular antioxidant enzyme expression and reduced ROS.
GHK-Cu suppressed inflammatory cytokine production and reduced pro-inflammatory immune signaling.
Study demonstrating topical GHK-Cu improved photoaging signs and enhanced dermal remodeling.
Comprehensive gene expression review showing GHK-Cu modulates over 4,000 human genes (32% of genome), with patterns that reverse age-related expression changes in tissue repair and inflammation.
Human trial demonstrating topical GHK-Cu improved facial skin texture, reduced wrinkle depth, and enhanced firmness.
Study demonstrating GHK-Cu upregulated NGF expression and provided neuroprotection in injury models.
Comprehensive gene expression study showing GHK-Cu regulated 350+ genes associated with tissue remodeling and healing.
Research showing GHK-Cu enhanced antimicrobial peptide production and reduced infection in wounds.
Mechanistic study showing GHK-Cu regulated TGF-β signaling to promote healthy tissue remodeling.
Study showing GHK-Cu stimulated hair growth and extended anagen phase in hair follicles.
Study demonstrating GHK-Cu enhanced corneal epithelial cell migration and accelerated wound healing in vitro.
Review of GHK-Cu antioxidant and anti-degenerative properties including protection from oxidative stress, stimulation of collagen/glycosaminoglycan synthesis, and promotion of wound healing.
In vitro study demonstrating GHK-Cu enhanced Type I, II, III collagen and hyaluronic acid production in fibroblasts.
In vitro and in vivo study showing GHK-Cu stimulated neovascularization in healing wounds.
Research showing GHK-Cu upregulated TIMP expression while reducing MMP activity, protecting collagen.
GHK-Cu topical application significantly accelerated dermal wound healing and improved scar appearance.
Overview of GHK-Cu cosmetic science: collagen stimulation, wound healing acceleration, and skin remodeling through copper-mediated enzymatic pathways.
12-week facial study showing GHK-Cu cream improved skin laxity, firmness, and clarity while reducing fine lines. Skin thickness increased on ultrasound measurement.
The presence of a study does not mean an effect is established. Sample sizes vary widely, many trials are small pilots or animal work, and individual findings may not replicate. The overall evidence level for GHK-Cu is L3 (Emerging Clinical Evidence): pilot human studies or limited clinical trials available. Treat each study as one data point, not a conclusion.
PeptideMark indexes 96 studies on GHK-Cu: 8 human studies, 42 animal studies, 35 in-vitro, and 11 reviews. The current evidence level is L3 — emerging clinical evidence.
The earliest indexed peer-reviewed study on GHK-Cu in the PeptideMark library was published in 2002 (Journal of the American Academy of Dermatology). Research activity has continued through 2019.
Duration varies by indication and phase. Early-phase pharmacokinetic and safety studies typically run 4–12 weeks. Phase 2 efficacy trials commonly span 12–26 weeks. Phase 3 registration trials for chronic indications often extend 52–104 weeks. Review individual trial records on ClinicalTrials.gov for specific durations.
Published research activity on GHK-Cu has slowed in recent years based on indexed studies. Ongoing investigator-initiated trials may exist that are not yet indexed.
Every study referenced here links to its PubMed record via the study ID. PeptideMark does not host full text; use the PubMed link to access abstracts and publisher sites for the primary literature.